Lv11
16 积分 2024-01-22 加入
Empagliflozin as add‐on to metformin in people with Type 2 diabetes
7小时前
待确认
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
7小时前
已完结
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
7小时前
已完结
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
2个月前
已完结
Systemic sclerosis in adults. Part II: management and therapeutics
2个月前
已完结
类风湿关节炎患者功能受限特征及相关因素分析
2个月前
已完结
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes
2个月前
已完结
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus
2个月前
已完结
系统性硬化病诊疗规范
2个月前
已完结
皖公网安备34019202002308
